WE-D-M100J-05: Estimation of Tumor Control Probability Model Parameters for Early Stage Non-Small-Cell Lung Cancer (NSCLC)

2007 ◽  
Vol 34 (6Part21) ◽  
pp. 2603-2603
Author(s):  
V Semenenko ◽  
E Gore ◽  
X Li
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Probability Model ◽  
Small Cell ◽  
Tumor Control ◽  
Model Parameters ◽  
Tumor Control Probability ◽  
Small Cell Lung

Inoperable Early-Stage Non–Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy

2022 ◽  
Author(s):  
Megan E. Daly
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Systemic Therapy ◽  
Early Stage ◽  
Small Cell ◽  
Phase Iii ◽  
Tumor Control ◽  
Stereotactic Ablative Radiotherapy ◽  
Small Cell Lung

Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable, early-stage non–small-cell lung cancer. SABR results in high rates of in-field tumor control, but among larger and more biologically aggressive tumors, regional and distant failures are problematic. Cytotoxic chemotherapy is rarely used in this patient population and the benefit is unclear. Alternative systemic therapy options with a milder side-effect profile are of considerable interest, and several randomized phase III trials are currently testing immune checkpoint inhibitors in this setting. We review the rationale, data, and ongoing studies evaluating systemic therapy in medically inoperable, early-stage non–small-cell lung cancer treated with SABR.

Sign in / Sign up

Export Citation Format

Share Document